吉西他滨联合白蛋白紫杉醇一线治疗老年转移性胰腺癌:跨越年龄界限?
该研究回顾性收集156例≥65岁转移性胰腺癌患者接受吉西他滨联合白蛋白紫杉醇(Gem-Nab)一线治疗的数据,按年龄<70岁(65例)和≥70岁(91例)分组。两组毒性谱相似,但≥70岁组全级别贫血和神经毒性发生率较低,且白蛋白紫杉醇剂量强度较低;两组缓解率、中位总生存和无进展生存均相似,起始剂量不影响PFS和OS。结论认为Gem-Nab在老年转移性胰腺癌患者中有效且可行,与临床试验中一般人群结果一致,对老年患者可考虑轻度剂量调整以改善安全性而不影响疗效。
要点
- Gem-Nab在≥65岁转移性胰腺癌患者中有效,疗效与临床试验一般人群一致。
- ≥70岁患者全级别贫血和神经毒性发生率较低,与白蛋白紫杉醇剂量强度较低相关。
- 起始剂量不影响无进展生存和总生存,老年患者可考虑轻度剂量调整以改善安全性。
核心结论
- Gem-Nab在老年转移性胰腺癌患者中具有活性和有效性,结果与临床试验中纳入的一般转移性胰腺癌人群一致。
- 对老年患者可考虑轻度剂量调整以改善安全性而不损害疗效。
研究设计与样本
- 回顾性收集156例≥65岁转移性胰腺癌患者接受Gem-Nab一线治疗的数据。
- 按年龄分层:<70岁为第1组(65例),≥70岁为第2组(91例)。
主要发现
- 中位年龄71岁(范围65-87岁)。
- 两组毒性谱相似,但全级别贫血发生率第1组92.1% vs 第2组78.7%(p=0.04),神经毒性发生率第1组61.9% vs 第2组40.4%(p=0.02)。
- 第2组白蛋白紫杉醇剂量强度较低(83.3% vs 90.5%,p=0.04)。
- 总体缓解率25.6%(第1组20.0% vs 第2组29.7%,p=0.12)。
- 中位随访26.5个月,两组中位总生存和无进展生存相似(p>0.05);Gem-Nab起始剂量不影响PFS和OS(p>0.05)。
临床怎么用
- Gem-Nab可作为老年转移性胰腺癌患者的一线治疗选择。
- 对老年患者可考虑轻度剂量调整以改善安全性,而不影响疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gemcitabine plus nab-paclitaxel (Gem-Nab) represents a standard first-line treatment for metastatic pancreatic cancer (mPC), but few data are available for elderly patients. We aimed to add evidence about safety and efficacy of Gem-Nab in this population. METHODS: We collected data of 156 patients with mPC aged ≥65 years receiving Gem-Nab. Patients were stratified according to age: <70 (group 1: 65 patients) and ≥70 years (group 2: 91 patients). RESULTS: The median age was 71 years (range: 65-87 years). The toxicity profile was similar between group 1 and 2, except for all-grade anaemia (92.1% vs. 78.7%, respectively; p = 0.04) and neurotoxicity (61.9% vs. 40.4%, respectively; p = 0.02), also as a result of a lower dose intensity of nab-paclitaxel (83.3% vs. 90.5%, respectively; p = 0.04) administered to oldest patients. The response rate was 25.6% (group 1 vs. 2: 20.0% vs. 29.7%; p = 0.12). After a median follow-up of 26.5 months, median overall survival (OS) and progression-free survival (PFS) were similar between the groups (p > 0.05). The starting dose of Gem-Nab did not affect PFS and OS (p > 0.05). CONCLUSION: Gem-Nab is active and effective in older patients with mPC, with the results in line with the general mPC population enrolled in clinical trials. Mild dose modifications for elderly patients might be considered to improve safety without impairing efficacy.
引用
- Vivaldi C, Salani F, Rovesti G, et al. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Eur J Cancer. 2020. PMID: 32750500. doi:10.1016/j.ejca.2020.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。